1 domain / 2 areas / 1 specialization
Boxer Capital
Data updated
Boxer Capital is a biotechnology investment firm and private investment fund based in San Diego, California. Its public materials describe it as a full life cycle investor focused on fundamental, research-based investing across private and public markets, with activity spanning early-stage through late-stage biotech.
It matters to the psychedelic ecosystem because its investing style overlaps with the kinds of capital needed by drug-development companies, including crossover, private, and public-market financing. Boxer Capital’s public disclosures emphasize investing across the drug development lifecycle and supporting therapeutics companies from company formation through late-stage development, which can make it relevant to psychedelic medicine companies even when they are not explicitly psychedelic-focused.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- GH ResearchSeries B - undisclosed - Apr 1, 2021
- Cybinregistered direct offering - undisclosed - Jun 1, 2025
Boxer Capital is a San Diego-based biotech investor with a research-driven, full life cycle approach that spans private company formation, crossover rounds, and public-market positions. The firm says it invests across the drug lifecycle and has historically backed therapeutics companies from early discovery through late-stage clinical and commercial development. Its relevance to the psychedelic space is indirect but meaningful: that same capital model can support psychiatry, CNS, and novel-therapeutics companies moving through rigorous drug development and public-market financing.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Apr 1, 2021
Series B - undisclosed
Boxer Capital was named among the new investors in this psychedelics-focused clinical-stage company.
GH Research Announces Closing of $125 Million Oversubscribed Series B FinancingJun 1, 2025
registered direct offering - undisclosed
Boxer Capital was listed among the investors in a financing for the public psychedelic biotechnology company.
Cybin Announces FinancingQuick Facts
- Founded
- 2005
- HQ
- San Diego, California, United States
- Website
- Visit